Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GBA1 | P04062 | 1/20 | 0.37 |
| ▸ | PYGM | P11217 | 1/20 | 0.36 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.34 |
| ▸ | PYGB | P11216 | 1/20 | 0.34 |
| ▸ | CDA | P32320 | 8/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.33 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.33 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.33 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180561 | 1.00 | LMNA (0.37) | LMNAGBA1PYGMDUSP3PYGB | |
| SCHEMBL24917500 | 1.00 | LMNA (0.37) | LMNAGBA1PYGMDUSP3PYGB | |
| SCHEMBL5356245 | 0.82 | OGA (0.43) | — | |
| SCHEMBL17468114 | 0.77 | MAPT (0.42) | LMNAGBA1CDAMAPTSLC28A1 | |
| SCHEMBL21001786 | 0.77 | MAPT (0.42) | LMNAGBA1CDAMAPTSLC28A1 | |
| SCHEMBL2479127 | 0.77 | MAPT (0.42) | LMNAGBA1CDAMAPTSLC28A1 | |
| SCHEMBL4750881 | 0.77 | MAPT (0.42) | LMNAGBA1CDAMAPTSLC28A1 | |
| SCHEMBL20640660 | 0.77 | MAPT (0.42) | LMNAGBA1CDAMAPTSLC28A1 | |
| SCHEMBL12835327 | 0.75 | ALDH1A1 (0.36) | LMNAGBA1PYGBCDAMAPT | |
| SCHEMBL16168023 | 0.75 | ALDH1A1 (0.36) | LMNAGBA1PYGBCDAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | LYCIA THERAPEUTICS, INC. | 2023-08-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250091-A1 | ASGPR CELL SURFACE RECEPTOR BINDING COMPOUNDS AND CONJUGATES | ASGR1, LAMP2, FCGR2A | LMNA 2495/4885GBA1 21/4885PYGM 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.